P3 Health Partners Announces Second Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

Event · Earnings
Also in this documentGuidance · raise

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Aug 10, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PIII
Bullish
high confidence
Mentioned
$PIII
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PIIIBullishHigh
01

Why it matters

Q2 showed a swing to positive net income and a large improvement in adjusted EBITDA versus the prior-year quarter, prompting management to raise full-year adjusted EBITDA guidance.

02

Market read

Traders can update models immediately using the revised 2026 adjusted EBITDA range and the reported Q2 profitability metrics, with the call at 4:30 PM ET as a near-term catalyst.

03

What to watch

At-risk membership declined 10% YoY to ~105,000, which could offset margin gains if payer rationalization continues or if rate progression slows.

Relevance 7/10Novelty 9/10Timing: after-hours disclosure filed Aug 10, 2026, ahead of 4:30 PM ET conference call

Background

P3 Health Partners is a population health management company reporting quarterly results and providing revised full-year non-GAAP guidance.

Company-level read

Ticker impact

$PIIIBullishHigh confidence
Context

P3 reported Q2 2026 results and raised full-year 2026 adjusted EBITDA guidance to $80 million to $110 million.

Expected impact

Likely positive near-term bias as traders price the raised adjusted EBITDA range and improved medical margin/EBITDA trajectory.

Evidence & confidence

The filing includes specific Q2 adjusted EBITDA of $54.4 million and a revised full-year adjusted EBITDA range ($80m to $110m), both time-sensitive and directly tied to management’s outlook.

Market effects

Reinforces investor appetite for value-based population health operators showing contract and network execution improvements.

No specific regional spillover beyond US healthcare services.

Limited, company-specific US healthcare services update.

Counterpoint

Adjusted EBITDA and medical margin include favorable payer settlements and prior-year development, so the quality and sustainability of the improvement may be questioned.

Key entities

  • P3 Health Partners Inc.

    NASDAQ-listed population health management company filing an 8-K with Q2 results and revised 2026 adjusted EBITDA guidance.

  • Dr. Aric Coffman

    CEO quoted stating Q2 execution supports raising full-year 2026 adjusted EBITDA outlook.

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.